{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:45:32Z","timestamp":1760147132057,"version":"build-2065373602"},"reference-count":52,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Two main types of oral anticoagulants are available in France: vitamin K antagonists (VKA) and, more recently, direct oral anticoagulants (DOAC). The benefit\u2013risk profile appears to be favorable for DOAC, which is as effective as VKA but safer (fewer cases of severe and cerebral bleeding). In a study in 2017, we observed that older adults did not seem to receive the same modalities of oral anticoagulants as younger individuals for various reasons. To assess anticoagulation prescribing practices over time, we repeated this cross-sectional study by comparing very old individuals taking DOAC to those taking VKA. Ambulatory individuals aged 80 years and older were included. They were affiliated with the Mutualit\u00e9 Sociale Agricole of Burgundy and were refunded for a medical prescription of oral anticoagulation in March 2021. The demographic characteristics, registered chronic diseases (RCD), number and types of prescribed drugs, and mortality of the DOAC group and the VKA group were compared. A total of 4275 subjects were included in the study: 67.44% (2883) received DOAC and 32.56% (1392) received VKA. The two groups were similar in age. In the DOAC group, there were more women (54.98% vs. 46.98%) (p &lt; 0.001), fewer RCD (91.47% vs. 93.68%) (p = 0.014), and lower rates of venous thromboembolism (2.53% vs. 6.75%) (p &lt; 0.001), severe heart failure (56.50% vs. 68.03%) (p &lt; 0.001), and severe kidney diseases (1.38% vs. 3.59%) (p &lt; 0.001), but there were more subjects with Alzheimer\u2019s disease (7.49% vs. 4.31%) (p = 0.001). Individuals in the DOAC group had fewer prescriptions of furosemide (48.53% vs. 55.75%) (p &lt; 0.001) and fibrates (2.32% vs. 3.88%) (p = 0.044). They also had more prescriptions of proton pump inhibitors (43.95% vs. 39.44%) (p = 0.006) and antirheumatics (1.60% vs. 0.65%) (p = 0.009) than those in the VKA group. There was no difference in mortality. This study revealed that prescribing practices for DOAC have changed over time.<\/jats:p>","DOI":"10.3390\/ijerph20021448","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T01:30:26Z","timestamp":1673573426000},"page":"1448","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021"],"prefix":"10.3390","volume":"20","author":[{"given":"Chana","family":"Azzoug","sequence":"first","affiliation":[{"name":"\u201cP\u00f4le Personnes \u00c2g\u00e9es\u201d, Hospital of Champmaillot, University Hospital, 21079 Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Nu\u00e9mi","sequence":"additional","affiliation":[{"name":"Medical Information Department, University Hospital, 21079 Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Menu","sequence":"additional","affiliation":[{"name":"\u201cMutualit\u00e9 Sociale Agricole\u201d of Burgundy Franche Comt\u00e9, 21000 Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"De Maistre","sequence":"additional","affiliation":[{"name":"Haemostasis Unit, University Hospital, 21079 Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3504-7250","authenticated-orcid":false,"given":"Mathieu","family":"Boulin","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospital, 21079 Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-554X","authenticated-orcid":false,"given":"Alain","family":"Putot","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, Pays du Mont Blanc Hospital, 74700 Sallanches, France"},{"name":"Physiopathologie et \u00c9pid\u00e9miologie C\u00e9r\u00e9bro-Cardiovasculaires (PEC2), EA 7460, University of Burgundy, 21000 Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5518-9803","authenticated-orcid":false,"given":"Patrick","family":"Manckoundia","sequence":"additional","affiliation":[{"name":"\u201cP\u00f4le Personnes \u00c2g\u00e9es\u201d, Hospital of Champmaillot, University Hospital, 21079 Dijon, France"},{"name":"INSERM U-1093, Cognition, Action and Sensorimotor Plasticity, University of Burgundy, 21000 Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"ref_1","unstructured":"(2022, August 30). Population Par \u00c2ge\u2014Tableaux de l\u2019\u00e9conomie Fran\u00e7aise | Insee. Available online: https:\/\/www.insee.fr\/fr\/statistiques\/3303333?sommaire=3353488."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1447-0594.2011.00776.x","article-title":"Toward the Realization of a Better Aged Society: Messages from Gerontology and Geriatrics: Realization of a Better Aged Society","volume":"12","author":"Arai","year":"2012","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke Severity in Atrial Fibrillation","volume":"27","author":"Lin","year":"1996","journal-title":"Stroke"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"ISTH Steering Committee for World Thrombosis Day (2014). Thrombosis: A Major Contributor to the Global Disease Burden. J. Thromb. Haemost., 12, 1580\u20131590.","DOI":"10.1111\/jth.12698"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral Anticoagulant Therapy","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.revmed.2006.09.004","article-title":"La Vitamine K Epoxyde R\u00e9ductase: Du Sang Neuf dans les Traitements Anticoagulants Oraux","volume":"27","author":"Loriot","year":"2006","journal-title":"Rev. Med. Interne"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/jth.12127","article-title":"The History and Historical Treatments of Deep Vein Thrombosis","volume":"11","author":"Galanaud","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"EAFT (European Atrial Fibrillation Trial) Study Group (1993). Secondary Prevention in Non-Rheumatic Atrial Fibrillation after Transient Ischaemic Attack or Minor Stroke. Lancet, 342, 1255\u20131262.","DOI":"10.1016\/0140-6736(93)92358-Z"},{"key":"ref_9","unstructured":"(2022, August 31). Les Anticoagulants Oraux. Available online: https:\/\/www.has-sante.fr\/jcms\/c_2851086\/fr\/les-anticoagulants-oraux."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e007338","DOI":"10.1161\/JAHA.117.007338","article-title":"Evidence Gaps in the Era of Non\u2013Vitamin K Oral Anticoagulants","volume":"7","author":"Aronis","year":"2018","journal-title":"J. Am. Heart. Assoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J. Am. Heart. Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.revmed.2020.05.026","article-title":"Anticoagulants Oraux Directs: Dans Quelles Indications? Lequel Prescrire? Pour ou Contre chez les Personnes Fragiles et dans les Situations Atypiques? Quelle Surveillance et Gestion des Accidents H\u00e9morragiques?","volume":"41","author":"Hoffmann","year":"2020","journal-title":"Rev. Me\u00e9d. Interne"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR Recommendations for the Management of Antiphospholipid Syndrome in Adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart. J."},{"key":"ref_15","first-page":"CD009893","article-title":"Direct Thrombin Inhibitors versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in People with Non-valvular Atrial Fibrillation","volume":"2014","author":"Salazar","year":"2014","journal-title":"Cochrane. Database. Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and Safety of Novel Oral Anticoagulants as Compared with Vitamin K Antagonists in the Treatment of Acute Symptomatic Venous Thromboembolism: A Systematic Review and Meta-Analysis","volume":"12","author":"Kooiman","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1093\/eurheartj\/suab150","article-title":"Non-Vitamin K Antagonist Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation","volume":"24","author":"Giugliano","year":"2022","journal-title":"Eur. Heart. J. Suppl."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Manckoundia, P., Nuemi, G., Hacquin, A., Menu, D., Rosay, C., Vovelle, J., Nuss, V., Baudin-Senegas, C., Barben, J., and Putot, A. (2021). Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18094443"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1093\/eurheartj\/ehab648","article-title":"Corrigendum to: 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_21","unstructured":"(2022, August 31). ICD-10 Version 2016. Available online: https:\/\/icd.who.int\/browse10\/2016\/en."},{"key":"ref_22","unstructured":"(2022, August 31). R: The R Project for Statistical Computing. Available online: https:\/\/www.r-project.org\/."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/ehjqcco\/qcab025","article-title":"Two-Year Outcomes of More than 30 000 Elderly Patients with Atrial Fibrillation: Results from the All Nippon AF In the Elderly (ANAFIE) Registry","volume":"8","author":"Yamashita","year":"2022","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_24","first-page":"341","article-title":"Anticoagulant Treatment in Elderly Patients with Atrial Fibrillation: A Position Paper","volume":"17","author":"Hanon","year":"2019","journal-title":"Geriatr. Psychol. Neuropsychiatr. Vieil."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamainternmed.2022.4918","article-title":"Qualitative Analysis of Patient\u2013Physician Discussions Regarding Anticoagulation for Atrial Fibrillation","volume":"182","author":"Martinez","year":"2022","journal-title":"JAMA. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/jth.14793","article-title":"Switching from Vitamin K Antagonists to Direct Oral Anticoagulants: Treatment Satisfaction and Patient Concerns","volume":"18","author":"Toorop","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ancard.2017.02.005","article-title":"Observance du Traitement Anticoagulant Oral chez le Sujet \u00c2g\u00e9 \u00e0 l\u2019\u00e8re des anticoagulants Oraux Directs","volume":"66","author":"Drouin","year":"2017","journal-title":"Ann. Cardiol. Angeiol. (Paris)"},{"key":"ref_28","first-page":"e72","article-title":"2020 ACC\/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ehjcvp\/pvaa117","article-title":"Effectiveness and Safety of Oral Anticoagulants among Non-Valvular Atrial Fibrillation Patients with Polypharmacy","volume":"7","author":"Lip","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/IJNRD.S105771","article-title":"Direct Oral Anticoagulants in Patients with Chronic Kidney Disease: Patient Selection and Special Considerations","volume":"10","author":"Lutz","year":"2017","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjh.15564","article-title":"The Use of Direct Oral Anticoagulants in Chronic Kidney Disease","volume":"183","author":"Parker","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1160\/TH11-10-0721","article-title":"Impact of Glomerular Filtration Estimate on Bleeding Risk in Very Old Patients Treated with Vitamin K Antagonists: Results of EPICA Study on the Behalf of FCSA (Italian Federation of Anticoagulation Clinics)","volume":"107","author":"Poli","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"L12","DOI":"10.1093\/eurheartj\/suz238","article-title":"Frailty in Patients with Heart Failure","volume":"21","author":"Vitale","year":"2019","journal-title":"Eur. Heart. J. Suppl."},{"key":"ref_34","first-page":"447","article-title":"Coagulation in Liver Disease","volume":"41","author":"Hoffman","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1007\/s12325-020-01307-z","article-title":"Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review","volume":"37","author":"Ballestri","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e011112","DOI":"10.1161\/JAHA.118.011112","article-title":"Effectiveness and Safety of Non\u2013Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation","volume":"8","author":"Lee","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/1060028019841582","article-title":"Direct Oral Anticoagulants in Chronic Liver Disease","volume":"53","author":"Steuber","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_38","unstructured":"European Medicines Agency (2022, August 31). Eliquis\u00ae\u2014Summary of Product Characteristics. Available online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhepr.2019.02.006","article-title":"Anticoagulation in the Cirrhotic Patient","volume":"1","author":"Turco","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2020.0652","article-title":"Off-Label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi","volume":"5","author":"Robinson","year":"2020","journal-title":"JAMA. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.4103\/1673-5374.303029","article-title":"Direct Oral Anticoagulants: A New Therapy against Alzheimer\u2019s Disease?","volume":"16","author":"Grossmann","year":"2021","journal-title":"Neural. Regen. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/ggi.12805","article-title":"Diabetes Mellitus, Hypertension and Frailty: A Population-Based, Cross-Sectional Study of Mexican Older Adults","volume":"17","author":"Cesari","year":"2017","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in Elderly People","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.7326\/M20-7141","article-title":"Frailty and Clinical Outcomes of Direct Oral Anticoagulants versus Warfarin in Older Adults with Atrial Fibrillation: A Cohort Study","volume":"174","author":"Kim","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","article-title":"Guidance for the Practical Management of the Direct Oral Anticoagulants (DOACs) in VTE Treatment","volume":"41","author":"Burnett","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1038\/s41598-017-03596-x","article-title":"Temporal Trends in Initiation of VKA, Rivaroxaban, Apixaban and Dabigatran for the Treatment of Venous Thromboembolism\u2014A Danish Nationwide Cohort Study","volume":"7","author":"Pallisgaard","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus Warfarin in Patients with Atrial Fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ana.26267","article-title":"Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation","volume":"91","author":"Polymeris","year":"2022","journal-title":"Ann. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"9851307","DOI":"10.1155\/2019\/9851307","article-title":"Direct Oral Anticoagulant Use and Risk of Diverticular Hemorrhage: A Systematic Review of the Literature","volume":"2019","author":"Turpin","year":"2019","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1055\/s-0040-1710592","article-title":"Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis","volume":"120","author":"Hansten","year":"2020","journal-title":"Thromb. Haemost."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/2\/1448\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:04:51Z","timestamp":1760119491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/2\/1448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijerph20021448"],"URL":"https:\/\/doi.org\/10.3390\/ijerph20021448","relation":{},"ISSN":["1660-4601"],"issn-type":[{"type":"electronic","value":"1660-4601"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}